CNS PHARMACEUTICALS INC (CNSP)

Company Profile

CNS Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The firm's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The firm is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Company Info

CNS PHARMACEUTICALS INC

2100 West Loop S Ste 900

Houston TEXAS 77027

P: 18009469185

CEO: John Climaco

Employees: 3

Website: https://cnspharma.com/